Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dimethyl glutamate

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

Biogen Idec building

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

Pivotal AHEAD 3-45 programme initiated this week

- PMLiVE

Biogen completes filing for highly-anticipated Alzheimer’s drug

FDA has 60 days to decide whether to accept filing for review

Alzheimer’s: the search for a cure

Will Biogen’s aducanumab re-energise the hunt for pharma’s white whale?

- PMLiVE

Biogen joins COVID-19 efforts with $10m support fund

Funds will be used to address 'immediate critical needs'

- PMLiVE

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Gains rights to tau-targeting drug ST-501 as part of broader alliance

What gets on your nerves?

COUCH Health

- PMLiVE

Biogen triumphs over Mylan’s Tecfidera patent challenge

Shares in Biogen skyrocketed by 32% following ruling

- PMLiVE

Will biosimilars ever catch on in the US?

Why biosimilars are viewed in the US as ‘me too’ drugs rather than as just-as-good alternatives to branded products

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

- PMLiVE

Novartis gets EU approval for multiple sclerosis therapy Mayzent

Offers subgroup of patients an important new treatment option

- PMLiVE

Biogen bets on Ionis’ early-stage Alzheimer’s drug

Paid $45m upfront with potential milestones of up to $155m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links